New malaria drug delayed over financial dispute between Novartis and WHO

Production of a new, more effective anti-malaria drug that could save hundreds of thousands of lives is being delayed amid a financial disagreement. At the core of the dispute is Swiss pharmaceutical firm Novartis’ demand that the World Health Organization sign a contract to buy the anti-malaria drug Coartem for three years.  Financial Times (London) (2/19)